$CYAD News
Last published 1mo ago
- 1mo agoCYADCelyad Oncology Reports First Half Year 2026 ResultsBusiness WireRegulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced its financial results for the first half year 2026 ended June 30, 2026. First Half 2026 financial
- 3mo agoCYADPublication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)Business WireRegulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad Oncology"), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of
- 3mo agoCYADCelyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)Business WireRegulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad Oncology"), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of
- 4mo agoCYADCelyad Oncology Announces €500,000 Private PlacementBusiness WireRegulatory News: Celyad Oncology SA (Euronext: CYAD) (the "Company" or "Celyad Oncology"), today announced that it has entered into a subscription agreement for a private placement financing (the
- 3y agoCYADCelyad Oncology announces receipt of Nasdaq delisting noticeGlobeNewswireMONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor
- 3y agoCYADCelyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From NasdaqGlobeNewswireMONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor
- 3y agoCYADCelyad Oncology reports first quarter 2023 financial results and recent business highlightsGlobeNewswirePresentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR
- 3y agoCYADCelyad Oncology announces receipt of Nasdaq initial notification on ADS bid priceGlobeNewswireMONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor
- 3y agoCYADCelyad Oncology announces receipt of Nasdaq noticeGlobeNewswireMONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor
- 3y agoCYADCelyad Oncology SA (CYAD) Q4 2022 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoCYADPARIS:CYADCelyad Oncology appoints Georges Rawadi as its new CEOGlobeNewswireMONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor
- 3y agoCYADPARIS:CYADCelyad Oncology reports full year 2022 financial results and recent business highlightsGlobeNewswireStarting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of
- 3y agoCYADPARIS:CYADCelyad Oncology to announce full year 2022 financial results and host conference callGlobeNewswireMONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies
- 3y agoCYADPARIS:CYADCelyad Oncology announces non-cash impairmentGlobeNewswireMONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies
- 3y agoCYADPARIS:CYADREPEAT -- Celyad Oncology SA - Letter to ShareholdersGlobeNewswireMONT-SAINT-GUIBERT, Belgium, March 01, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the "Company"), with important
- 3y agoCYADPARIS:CYADCelyad Oncology SA - Letter to ShareholdersGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the "Company"), with important
- 3y agoCYADPARIS:CYADCelyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01GlobeNewswireMONT-SAINT-GUIBERT, Belgium, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies
- 3y agoCYADPARIS:CYADCelyad Oncology provides fourth quarter 2022 business update and 2023 outlookGlobeNewswireCelyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property
- 3y agoAZNCRDFCYADRIGL+2Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical TrialsPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., Jan. 19, 2023 /PRNewswire/ -- Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T
- 3y agoCYADPARIS:CYADCelyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual propertyGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies
- 4y agoCYADPARIS:CYADCelyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswireCompany continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discoveryClinical updates expected by end of year for the Phase 1 dose-escalation IMMUNICY-1
- 4y agoCYADPARIS:CYADCellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations TransactionGlobeNewswireGOSSELIES, Belgium and MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology comp
- 4y agoCYADCellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations TransactionBusiness WireCellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T)
- 4y agoCYADPARIS:CYADCelyad Oncology Reports First Half 2022 Financial Results and Recent Business HighlightsGlobeNewswireEnrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM) In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical
- 4y agoCYADPARIS:CYADCelyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b TrialGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 4y agoCYADPARIS:CYADCelyad Oncology to Announce First Half 2022 Financial Results and Host Conference CallGlobeNewswireMONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 4y agoCYADPARIS:CYADCelyad Oncology Announces Leadership UpdatesGlobeNewswireMONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) th
- 4y agoCYADPARIS:CYADInformation on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)GlobeNewswireMONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T)
- 4y agoCYADPARIS:CYADCelyad Oncology to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireMONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) the
- 4y agoCYADPARIS:CYADCelyad Oncology Announces First Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswireEnrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM) Dialogue continues with regulatory agencies concerning CYAD-101-002 Phase 1b t
- 4y agoCYADCelyad Oncology Reports Full Year 2021 Financial Results and Recent Business HighlightsGlobeNewswireHighlights Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM) patients Investigation ongoing of finding
- 4y agoCYADCelyad Oncology to Announce Full Year 2021 Financial Results and Host Conference CallGlobeNewswireMONT-SAINT-GUIBERT, Belgium, March 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for can
- 4y agoCYADCelyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b TrialGlobeNewswireMONT-SAINT-GUIBERT, Belgium, March 02, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) t
- 4y agoCYADCelyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b TrialGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) th
- 4y agoCYADCelyad Oncology Announces February 2022 Conference ScheduleGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 4y agoCYADCelyad Oncology Provides Outlook for 2022GlobeNewswireKEYNOTE-B79 and IMMUNICY-1 clinical trials evaluating the Company's allogeneic CAR T candidates, CYAD-101 and CYAD-211 respectively, expected to generate key data throughout 2022 Company's proprietary non-gene edited shRNA technology clinically valida
- 4y agoCYADInformation on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)GlobeNewswireMONT-SAINT-GUIBERT, Belgium, Dec. 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 4y agoCYADTransparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)GlobeNewswireMONT-SAINT-GUIBERT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 4y agoCYADCelyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b TrialGlobeNewswireKEYNOTE-B79 Phase 1b trial will evaluate CYAD-101 and KEYTRUDA® (pembrolizumab) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) ASCO-GI conference abstract accepted that highlights KEYNOTE-B79 clinical trial design
- 4y agoCYADTransparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)GlobeNewswireMONT-SAINT-GUIBERT, Belgium, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 4y agoCYADCelyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and ExpositionGlobeNewswireData continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs Management to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST MONT-
- 4y agoCYADCelyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group AffiliateGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) ("Celyad" or the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cel
- 4y agoAALARDXBIOLCSX+1Thinking about buying stock in Ardelyx, Celyad Oncology, CSX Corp, American Airlines, or Biolase?PR NewswireNEW YORK, Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, CYAD, CSX, AAL, and BIOL. To
- 4y agoCYADCelyad Oncology Announces $32.5 Million Private Placement with Fortress Investment GroupGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) ("Celyad" or the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cel
- 5y agoCYADCelyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingGlobeNewswirePreclinical data support armoring NKG2D CAR T cells with IL-18 to drive improved anti-tumor activity of the product candidate Development continues for second-generation multiplexing shRNA scaffold for novel non-gene edited CAR T candidates with desire
- 5y agoCYADCelyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewswirePhase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 followed by KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on track to begin by year-end 2021 Enrollment continues at the highest dose level in Phase 1 I
- 5y agoCYADCelyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and ExpositionGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 5y agoCYADCelyad Oncology Announces November 2021 Conference ScheduleGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 5y agoCYADInformation on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)GlobeNewswireMONT-SAINT-GUIBERT, Belgium, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc
- 5y agoCYADCelyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual MeetingGlobeNewswireMONT-SAINT-GUIBERT, Belgium, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for canc